STOCK TITAN

Marker Therapeutics (MRKR) Stock Price, News & Analysis

MRKR NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
68 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+54.7% close of November 19, 2026
1-year change
+9.6% closing prices, November 20, 2025 to November 20, 2026
1-month change
-6% closing prices, October 20, 2026 to November 20, 2026

Company Description

Marker Therapeutics, Inc. (Nasdaq: MRKR) is a Houston, Texas-based, clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The company was founded at Baylor College of Medicine and focuses on advancing its proprietary multi-antigen recognizing T cell (MAR-T) platform, a non-genetically modified cell therapy approach designed to expand tumor-specific T cells from a patient’s or donor’s blood.

According to the company, its MAR-T cell platform (formerly referred to as multiTAA-specific T cells) selectively expands T cells capable of recognizing a broad range of tumor antigens. These MAR-T cells can recognize hundreds of different epitopes within up to six tumor-specific antigens, which the company believes may reduce the possibility of tumor escape. Because the cells are not genetically engineered, Marker states that its product candidates may be easier and less expensive to manufacture and may have an improved safety profile compared to certain engineered T cell approaches, while still aiming to provide meaningful clinical benefits.

Core Technology and MAR-T Platform

MAR-T cells are central to Marker’s strategy. The platform uses non-genetically modified T cells that are expanded ex vivo to target multiple tumor-associated antigens. Marker reports that clinical trials conducted across various hematological and solid tumor indications have shown that its autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses in more than 200 treated patients. The company emphasizes the ability of MAR-T cells to recognize multiple antigens simultaneously as a way to address tumor heterogeneity and reduce the risk of relapse driven by single-antigen loss.

Marker’s MAR-T programs are supported by non-dilutive funding from U.S. state and federal agencies that support cancer research, including the National Cancer Institute of the National Institutes of Health, the Food and Drug Administration, and the Cancer Prevention and Research Institute of Texas (CPRIT). The company states that this funding strengthens its platform and helps preserve financial resources while it advances clinical development.

Lead Program: MT-601 in Lymphoma

Marker’s lead product candidate is MT-601, a multi-antigen recognizing T cell product that utilizes a non-genetically modified approach to target six tumor antigens that are upregulated in lymphoma cells: Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, and MAGEA-4. MT-601 is being investigated in the company-sponsored Phase 1 APOLLO trial (clinicaltrials.gov identifier: NCT05798897), a multicenter, open-label study evaluating safety, optimum dose, and preliminary efficacy in patients with relapsed or refractory lymphoma who have either failed anti-CD19 chimeric antigen receptor (CAR) T cell therapy or are not candidates for such therapy.

In updates from the APOLLO study, Marker has reported objective responses in patients with Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), including complete responses in a subset of heavily pre-treated patients. The company has also reported a favorable safety profile for MT-601, with no dose-limiting toxicities and no immune-effector cell associated neurotoxicity syndrome (ICANS) observed in the dose escalation cohort, and only limited low-grade cytokine release syndrome events. Marker has advanced APOLLO into a dose expansion phase, evaluating MT-601 at a pre-specified maximum dose level in patients with diffuse large B cell lymphoma (DLBCL) who have relapsed after or are ineligible for anti-CD19 CAR-T therapy.

Pancreatic Cancer Program

Beyond lymphoma, Marker is developing MT-601 for metastatic pancreatic cancer. The company has reported that it was awarded non-dilutive funding from the National Institutes of Health and CPRIT to support this program. Marker references clinical work from Baylor College of Medicine investigating multi-antigen targeted T cells in pancreatic ductal adenocarcinoma, which demonstrated encouraging disease control rates and a favorable safety profile when combined with frontline chemotherapy. Marker indicates that it has further advanced this technology under the MAR-T name and intends to incorporate improvements such as increasing the number of target antigens, using higher cell doses, and adding lymphodepletion to support T cell expansion in its pancreatic cancer program.

Off-the-Shelf MAR-T Program (MT-401-OTS)

Marker is also developing an Off-the-Shelf (OTS) MAR-T cell product, MT-401-OTS, for patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). MT-401-OTS is a multi-antigen recognizing T cell product that targets four tumor antigens upregulated in cancer cells: Survivin, PRAME, NY-ESO-1, and WT-1. It is being evaluated in the company-sponsored Phase 1 RAPID trial (clinicaltrials.gov identifier: NCT06552416), a multicenter, open-label study of escalating doses in AML or MDS.

Marker has reported that the first patient treated in the RAPID study received MT-401-OTS at the initial dose level and that the therapy was well tolerated with no treatment-related adverse events during the initial monitoring period. The company describes the OTS approach as using commercially available leukapheresis material from healthy donors to build a cellular inventory designed to cover a large patient population with partially human leukocyte antigen (HLA) matched material. Marker notes that this approach has been validated and extensively tested in prior clinical work at Baylor College of Medicine in the context of virus-specific T cells.

Manufacturing and Collaboration

To support clinical development of MT-601, Marker has entered into a collaboration with Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), for current good manufacturing practice (cGMP) manufacturing. Under this agreement, Cellipont provides technology transfer and cGMP manufacturing services to support scale-up and production of MT-601 for the APOLLO study. Marker states that this collaboration is intended to accelerate clinical supply and lay the foundation for potential later-stage development and commercial readiness.

Clinical and Research Foundations

Marker emphasizes that its origins at Baylor College of Medicine and the clinical experience with multi-antigen targeted T cells inform its current programs. The company notes that clinical trials enrolling more than 200 patients across various hematological and solid tumor indications have shown that its autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. In addition, Marker highlights scientific observations from its APOLLO study, including evidence that lymphodepletion can improve the expansion and persistence of MAR-T cells in vivo, which the company believes may influence anti-tumor activity.

Business Focus and Funding

Marker describes itself as a clinical-stage company that prioritizes the preservation of financial resources and focuses on operational excellence as it advances its pipeline. The company reports that it has received non-dilutive grant funding from multiple U.S. state and federal agencies, including the National Cancer Institute of the National Institutes of Health, the Food and Drug Administration, and CPRIT, to support programs such as MT-601 in lymphoma and pancreatic cancer and MT-401-OTS in AML and MDS. Marker also reports raising capital through equity offerings, including use of an at-the-market (ATM) facility, to extend its cash runway while continuing clinical development.

Stock and Regulatory Status

Marker Therapeutics, Inc. trades on Nasdaq under the ticker symbol MRKR. The company files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Form 10-K, Form 10-Q, and Form 8-K filings. Recent Form 8-K filings have covered topics such as clinical updates from the APOLLO study, initiation of the OTS program, financial results, changes in the company’s independent registered public accounting firm, and the appointment of a new member to the board of directors.

Stock Performance

$1.05
-3.67%
-0.04
After hoursChange vs the $1.09 closeLast updated: at
+9.6%
Performance 1 year
$17.5M
16.7M
Shares outstanding As of November 13, 2026.

Marker Therapeutics (MRKR) closed at $1.09 on November 20, 2026. Over the past 12 months, the price has gained 9.6%.

See what a $1,000 investment in MRKR would be worth today

Average down calculator for MRKR

MRKR Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Marker Therapeutics has 10 recent news articles, with the latest published on . Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include clinical trial, earnings, management, conferences. View all MRKR news →

Financial Highlights

Marker Therapeutics generated $3.5M in revenue in FY2025, operating income reached -$12.9M, and net income was -$12.2M. Diluted earnings per share stood at -$0.79. The company generated -$12.0M in operating cash flow. The current ratio was 8.39, measuring current assets divided by current liabilities.

$3.5M
Revenue (FY2025)
-$12.2M
Net Income (FY2025)
-$12.0M
Operating Cash Flow

Upcoming Events

Q1
2027
Q1 2027 Clinical

MT-601 Phase 1 start

Company-sponsored MT-601 Phase 1 trial start in locally advanced unresectable pancreatic cancer; funded by $2.6M FDA grant.

Marker Therapeutics has 1 upcoming scheduled event. The next event, "MT-601 Phase 1 start", is expected in Q1 2027. Investors can track these dates to stay informed about potential catalysts that may affect the MRKR stock price.

Short Interest History

Last 12 Months

Short interest in Marker Therapeutics (MRKR) currently stands at 176.1 thousand shares, up 61.4% from the previous reporting period, representing 1.1% of the float. Since November 2025, short interest has decreased by 24.6%.

Days to Cover History

Last 12 Months

Days to cover for Marker Therapeutics (MRKR) currently stands at 1.0 days, down 10.7% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 5.8 days.

MRKR Company Profile & Sector Positioning

Marker Therapeutics (MRKR) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing MRKR often look at related companies in the same sector, including Adicet Bio, Inc. (ACET), Akari Therapeutics plc (AKTX), LeonaBio, Inc. (LONA), Cocrystal Pharma, Inc. (COCP), and Cel-Sci Corporation (CVM). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MRKR's relative position within its industry.

Frequently Asked Questions

The current stock price of Marker Therapeutics (MRKR) is $1.05 in after-hours trading as of November 20, 2026.

The market cap of Marker Therapeutics (MRKR) is approximately $17.5M. Learn more about what market capitalization means .

The FY2025 revenue of Marker Therapeutics (MRKR) is $3.5M, from its most recent completed fiscal year.

The FY2025 net income of Marker Therapeutics (MRKR) is -$12.2M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Marker Therapeutics (MRKR) is -$0.79 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Marker Therapeutics (MRKR) is -$12.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Marker Therapeutics (MRKR), current assets divided by current liabilities, was 8.39 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Marker Therapeutics (MRKR) is -$12.9M for FY2025, its most recent completed fiscal year. Learn about operating income.